What is HC Wainwright’s Forecast for ALNY Q3 Earnings?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Investment analysts at HC Wainwright boosted their Q3 2025 earnings estimates for shares of Alnylam Pharmaceuticals in a research report issued to clients and investors on Tuesday, September 2nd. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings of $0.40 per share for the quarter, up from their prior estimate of ($0.64). HC Wainwright currently has a “Buy” rating and a $570.00 target price on the stock. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals’ Q4 2025 earnings at $1.38 EPS, FY2025 earnings at $0.84 EPS, FY2026 earnings at $17.37 EPS, FY2027 earnings at $32.51 EPS and FY2028 earnings at $34.46 EPS.

Several other equities research analysts also recently weighed in on ALNY. Wells Fargo & Company upped their target price on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an “equal weight” rating in a research note on Friday, August 1st. Wolfe Research raised shares of Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research note on Monday, August 4th. Raymond James Financial began coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They set an “outperform” rating and a $370.00 target price on the stock. Bank of America increased their price objective on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a “buy” rating in a research report on Friday, July 11th. Finally, Piper Sandler increased their price objective on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $417.38.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $452.00 on Friday. Alnylam Pharmaceuticals has a fifty-two week low of $205.87 and a fifty-two week high of $469.81. The firm’s 50 day moving average price is $387.47 and its 200 day moving average price is $309.30. The company has a market cap of $59.25 billion, a P/E ratio of -183.00 and a beta of 0.32. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. During the same period in the previous year, the firm earned ($0.13) EPS. The business’s revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. SVB Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $27,000. Park Square Financial Group LLC acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $28,000. Whipplewood Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 71 shares during the period. Bessemer Group Inc. boosted its stake in Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 69 shares during the period. Finally, Atlantic Union Bankshares Corp acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth $30,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 6,979 shares of the company’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $453.27, for a total value of $3,163,371.33. Following the completion of the transaction, the chief executive officer owned 56,221 shares in the company, valued at approximately $25,483,292.67. This represents a 11.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director owned 911 shares of the company’s stock, valued at approximately $397,724.38. The trade was a 97.18% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 57,594 shares of company stock worth $25,551,456. 1.50% of the stock is currently owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.